c-erbB-2/neu Oncogene and Ki-67 analysis in the assessment of palatal salivary gland neoplasms

Giannoni, Carla M.; El‐Naggar, Adel K.; Ordóñez, Nelson G.; Tu, Zhenxing; Austin, John R.; Luna, Mario A.; Batsakis, John G.

doi:10.1016/s0194-5998(95)70272-5

Cited by 52 publications

(33 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Concordance between HER-2 and HER-3 expression was reported, as well as with tubular/ cribriform histology. Giannoni et al [11] evaluated a series of palatal salivary gland neoplasms, of which 24 were ACCs, for HER-2/neu. Nine cases had a score of 2 or more on a scale from 0 to 3, and the authors reported a significant association between overexpression and poor clinical outcome among the ACC patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adenoid cystic carcinoma: A retrospective clinical review

Khan

DiGiovanna

Ross

et al. 2001

Intl Journal of Cancer

235

View full text Add to dashboard Cite

SUMMARY Adenoid cystic carcinoma (ACC) are uncommon tumors, representing about 10% to 15% of head and neck tumors. We compare the survival and control rates at our institution with those reported in the literature, and examine putative predictors of outcome. All patients registered with the tumor registry as having had ACC were identified. Demographic and survival variables were retrieved from the database. Additionally, a chart review of all patients was done to obtain specific information. Minor gland tumors were staged using the American Joint Committee on Cancer's criteria for squamous cell carcinomas in identical sites. Histopathologic variables retrieved included grade of the tumor, margins, and perineural invasion. Treatment modalities, field sizes, and radiation doses were recorded in applicable cases. An effort to retrieve archival tumor specimens for immunohistochemical analysis was undertaken. A total of 69 patients were treated for ACC from 1955 to 1999. One patient, who presented with fatal brain metastasis, was excluded from further analysis. Of the remaining 68 patients, 30 were men and 38 were women. The average age at diagnosis was 52 years, and mean follow-up was 13.2 years. Mean survival was 7.7 years. Overall survival (OS) rates at 5, 10, and 15 years were 72%, 44%, and 34%, and cause-specific survival was 83%, 71%, and 55%, respectively. Recurrence-free survival rates were 65%, 52%, and 30% at 5, 10, and 15 years, with a total of 29 of 68 (43%) eventually suffering a recurrence. Overall survival was adversely affected by advancing T and AJCC stage. Higher tumor grades were also associated with decreased OS, although the numbers compared were small. Primaries of the nasosinal region fared poorly when compared with other locations. Total recurrence-free survival, local and distant recurrence rates were distinctly better in primaries of the oral cavity/oropharynx when compared with those in other locations. Reduced distant recurrence-free survival was significantly associated with increasing stage. No other variables were predictive for recurrence. Additionally, we found that nasosinal tumors were more likely to display higher stage at presentation, and were more often associated with perineural invasion.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Some markers evaluated using immunohistochemistry include the epidermal growth factor receptor (EGF-R), HER-2, HER-3, p53, and proliferating cell nuclear antigen (PCNA) [10][11][12][13][14][15][16]. The resultant data for ACC have not been concordant.…”

Section: Introductionmentioning

confidence: 99%

Adenoid cystic carcinoma: A retrospective clinical review

Khan

DiGiovanna

Ross

et al. 2001

Intl Journal of Cancer

235

View full text Add to dashboard Cite

show abstract

“…It has to be emphasized in this context, that no valid reference system defining low or high levels of Ki-67 expression in salivary gland tumors has been established so far. 5,6 For statistical analysis, the results of Ki-67 staining were, therefore, classified by the authors through quantitative scoring in 3 grades (Grade 1, 1-25% stained cells; Grade 2, 26 -50% stained cells; Grade 3, Ͼ 50% stained cells).…”

Section: Methodsmentioning

confidence: 99%

“…Giannoni et al 6 reported that benign tumors in the minor salivary glands commonly showed a proliferation rate Ͻ 12%. However, Norgard et al 5 described a significantly higher rate of recurrent disease in patients with adenoid cystic carcinoma, with a proliferation rate (Ki-67) Ͼ 4%.…”

Section: Table 4 Prognostically Significant Factors In Sdc Clinical Cmentioning

confidence: 99%

Clinical and immunohistologic typing of salivary duct carcinoma

Jaehne

Roeser

Jaekel

et al. 2005

Cancer

291

350

View full text Add to dashboard Cite

BACKGROUNDDue to the low incidence of salivary duct carcinoma (SDC), only limited data in regard to the biologic behavior of this tumor and its immunohistochemical characteristics are available. The authors analyzed the clinical, molecular, and genetic profile of SDC and identified prognostic factors.METHODSThe follow‐up of 50 patients with SDC was obtained and paraffin‐embedded tumor samples were examined immunohistochemically. In all samples, the expression of Ki‐67, HER‐2, and the oncoproteins p16 and p53 was examined immunohistochemically, followed by a mutation analysis of p16 and p53. The survival rate was calculated by the Kaplan–Meier method and prognostic variables were analyzed with the log‐rank test.RESULTSSDC predominantly effected male patients (66%) in their 7th decade of life. SDC mainly occurred in the parotid gland (78%; submandibular gland, 12%; minor salivary glands, 10%). Approximately two‐thirds of the patients (33 of 50) presented with a T3/T4 tumor. In 28 patients (56%), cervical lymph node metastasis was present at the time of diagnosis. Local disease recurrence was observed in 48% of patients an average of 17.4 months after initial treatment. Distant disease metastasis developed in 48% of patients an average of 29 months after initial treatment. The average overall survival period was 56.2 months. In the current study, 20.6% of the probes with positive HER‐2/neu expression were (+++) positive. p53 was expressed in 83.9% of the tumor samples. In 11.8% of the tumor samples, there was a lack of p16 expression.CONCLUSIONSMutations of the p53 gene were more frequent in tumor samples with (++) and (+++) immunoreactivity and mainly affected exons 7 and 8. A mutation of the p16 gene was only found in 1 tumor sample. Expression of HER‐2/neu and p53 was statistically linked (P < 0.05) to early local disease recurrence, distant disease metastasis, and survival rates. Cancer 2005. © 2005 American Cancer Society.

show abstract

“…Although both tumors originate in the intercalated duct with the same cellular derivation (15) and secretion of proteins of the extracellular matrix (16), they exhibit the characteristic behavior of benign and malignant tumors, respectively, coupled with distinct proliferative activity (17)(18)(19)(20) The objective of this study was to evaluate the role of PCNA and AgNOR in the assessment of salivary gland tumor proliferation using a double staining technique.…”

Section: Introductionmentioning

confidence: 99%